SUNNYVALE, Calif., June 19, 2013 /PRNewswire/ — Pharmacyclics, Inc. (the “Company”) (Nasdaq: PCYC) today announced that The New England Journal of Medicine (NEJM) published results online of a Phase 1b/2 study evaluating the investigational oral Bruton’s tyrosine kinase (BTK) inhibitor…

Load More Related Articles
Load More In Entertainment